Summary Aim The aim of this study was to evaluate the efficacy and safety of liraglutide in adolescents with obesity. Materials and methods Patients ( n = 41) received injection liraglutide for at least 12 weeks and their pre‐baseline and post‐baseline characteristics were recorded and analysed. The key parameters analysed were weight, height, body mass index (BMI), fasting insulin and sugar, 1 h insulin and glucose, 2 h insulin and glucose, HbA1c, cholesterol, triglycerides, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, thyroid stimulating hormone and bone. Results There was a significant decrease ( p < 0.001) in body weight, BMI, fasting, 1 h post‐glucose tolerance and 2 h glucose tolerance. The changes from baseline to the end of study were for body weight − 6.5 ± 4.2 kg and BMI –2.35 ± 1.30 kg m −2 . Systolic blood pressure decreased from 119.25 ± 12.50 to 114.53 ± 9.53 mmHg and diastolic blood pressure from 70.69 ± 14.52 to 70.82 ± 8.85 mmHg. Liver enzymes had improved from 34.36 ± 12.23 (serum glutamic oxaloacetic transaminase), 38.08 ± 21.02 (serum glutamic pyruvic transaminase) to 33.52 ± 11.23 ( p = 0.03) and 33.99 ± 13.16 ( p = 0.01), respectively. Cholesterol and triglyceride had improved from 152.46 ± 24.74 and 124.41 ± 33.27 to 151.71 ± 23.46 ( p = 0.14) and 120.76 ± 26.22 ( p = 0.009), respectively. Conclusion In conclusion, treatment with liraglutide in adolescents with obesity offers an efficacious and safe alternative to patients who are not responding to other available modalities.

Cushing’s syndrome (CS) or hypercortisolism results from disruption of the hypothalamus-pituitary-adrenal (HPA) axis with the resultant increase in the circulating serum and urinary cortisol levels and lack of cortisol circadian rhythm. The resultant effects cause the physical manifestation of hypercortisolism. The appearance of Cushing’s disease in children is insidious, the most common features being growth failure, obesity, early puberty and facial appearance. We report a case of a 7-year-old male with a very unusual course of the disease, which could have led to diagnostic delays.

Newborns with a history of IUGR and HH have an increased risk of developing ketotic hypoglycaemia in the childhood period.

Osteogenesis imperfecta (OI) often leads to severe lower limb (LL) deformities due to recurrent fractures that significantly hamper ambulation. We describe our management experience of correction of LL deformities in four children with OI. Medical management consisted of peri and postoperative pamidronate therapy, calcium supplementation and rehabilitative care. Deformities were corrected with multiple osteotomies and intramedullary fixation by titanium elastic nails. At a mean follow-up of 30 months, all children have significantly reduced fracture incidence and have no evidence of recurrence of deformities with improved ambulatory status. We emphasize the importance of combined medical and surgical therapy for these patients.